PBI-4547 Improves Glucose Metabolism and Insulin Resistance, and Reduces Liver Damage in a High-Fat Diet Mouse Model of Obesity and Metaboli

June 22, 2018

 

Taken together, these results suggest that PBI-4547 offers the potential as a novel therapy for Non-alcoholic fatty liver disease (NAFLD), obesity, type 2 diabetes mellitus, and associated metabolic syndrome.

Previous Flipbook
PBI-4547 Prevents Progression of Prediabetic Condition to Type 1 Diabetes in NOD Mice
PBI-4547 Prevents Progression of Prediabetic Condition to Type 1 Diabetes in NOD Mice

PBI-4547 administration in prediabetic type 1 NOD mice significantly prevented the evolution to severe diab...

Next Flipbook
PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-
PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-

These results suggest that PBI-4050 is a strong potential candidate for the treatment of metabolic diseases...